Sangamo Therapeutics, Inc.
7000 Marina Blvd
Brisbane
CA
94005
United States
Tel: (510) 970-6000
Website: https://www.sangamo.com/
Email: hr@sangamo.com
About Sangamo Therapeutics, Inc.
Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but complementary technology platforms – gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. At Sangamo, we are passionate in developing genomic medicines to transform the lives of patients with serious diseases. We transform lives by building a robust, sustainable, differentiated, innovative, and high value genomic medicine pipeline that addresses patients with life-limiting conditions. Sangamo takes pride in being the first to edit endogenous human genes, first to treat patients with gene edited T cells, and first to treat patients with in vivo genome editing. Our top priority is to meet the needs of patients with commitment and compassion. Along with our commitment to science and to our patients, we also endeavor to create an inclusive environment that promotes and values diversity. Sangamo is a company where individuals can flourish, grow and develop their expertise.
We are seeking top talent to join our mission. Let’s build a better future together.
Stock Symbol: SGMO
600 articles with Sangamo Therapeutics, Inc.
-
Sangamo Therapeutics Announces Third Quarter 2021 Conference Call and Webcast
10/28/2021
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2021 financial results on Thursday, November 4, 2021.
-
Biopharma companies recognized that developing a therapy is merely the beginning of what is needed to connect patients with sickle cell disease to next-level therapies.
-
Mammoth will use the funds to build and broaden its stable of next-generation CRISPR products to detect and cure various diseases.
-
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences - Aug 31, 2021
8/31/2021
Sangamo Therapeutics, Inc., a genomic medicine company, announced that management will be participating in fireside chats at the following investor conferences
-
Sangamo Therapeutics Announces Participation at 2021 Wedbush PacGrow Healthcare Conference
8/9/2021
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in a fireside chat at the 2021 Wedbush PacGrow Healthcare Conference on Wednesday, August 11th at 2:55pm Eastern Time.
-
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
8/5/2021
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and second quarter 2021 financial results.
-
Sangamo Therapeutics Announces Second Quarter 2021 Conference Call and Webcast
7/29/2021
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its second quarter 2021 financial results after the market closes on Thursday, August 5, 2021.
-
The Biotech Bay region is home to 3,418 life sciences companies, and 96,574 employees making an average of $151,076.
-
Several biotech executives provided their thoughts on lessons learned from the pandemic and what they hope or expect to see moving forward in the industry.
-
Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, to Chief Financial Officer
5/24/2021
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Prathyusha Duraibabu, CPA, MBA as Senior Vice President and Chief Financial Officer, effective June 1, 2021. Ms. Duraibabu will lead all financial activities and report to the Chief Executive Officer.
-
Sangamo Therapeutics Announces Participation at Jefferies Healthcare Conference
5/21/2021
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 4 th at 11am Eastern Time.
-
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results
5/4/2021
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and first quarter 2021 financial results.
-
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences - May 03, 2021
5/3/2021
Sangamo Therapeutics, Inc., a genomic medicine company, announced that management will be participating in fireside chats at the following investor conferences
-
Sangamo Therapeutics Announces Presentations at 2021 Annual Meeting of the American Society of Gene & Cell Therapy
4/27/2021
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced upcoming data presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held May 11-14, 2021, in a virtual format.
-
Sangamo Therapeutics Announces First Quarter 2021 Conference Call and Webcast
4/27/2021
Sangamo Therapeutics, Inc., a genomic medicine company, announced that the Company has scheduled the release of its first quarter 2021 financial results after the market closes on Tuesday, May 4, 2021.
-
Sangamo Therapeutics Announces Participation at Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease
3/25/2021
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in the virtual Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease conference on April 1, 2021. S
-
Sangamo Announces EMA Releases Details Supporting Orphan Designation for BIVV003 for the Treatment of Sickle Cell Disease
3/17/2021
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) released details supporting the Orphan Designation of BIVV003, an investigational ex vivo gene-edited cell therapy product candidate currently being evaluated for the treatment of sickle cell disease in the Phase 1/2 PRECIZN-1 study
-
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
2/24/2021
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported fourth quarter and full year 2020 financial results and recent business highlights.
-
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences - Feb 18, 2021
2/18/2021
Sangamo Therapeutics, Inc., a genomic medicine company, announced that management will be participating in the following investor conferences
-
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2020 Conference Call and Webcast
2/17/2021
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year 2020 financial results after the market closes on Wednesday, February 24, 2021. The press release will be followed by a conference call at 5:00 p.m. ET,